Compare Cytokinetics Inc (CYTK) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Petróleo Brasileiro SA — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while Petróleo Brasileiro SA trades at $24.51 (market cap $149.03B). The key difference: Petróleo Brasileiro SA is far larger — about 17.5× Cytokinetics Inc's market cap, and Petróleo Brasileiro SA pays a 6.98% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Petróleo Brasileiro SA for 25 Days on average.
| CYTK | PBR | |
|---|---|---|
Market Cap | $8.50B | $149.03B |
Volume | 2,395,556 | 30,322,411 |
Sector | Health | Energy |
52-Week High | $87.26 | $24.69 |
52-Week Low | $54.76 | $11.54 |
Typical Hold Time | 19 Days | 25 Days |
Enterprise Value | $8.60B | $209.45B |
Dividend Yield | — | 6.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
Petrobras (PBR) trades at $23.99, up 0.8% with strong bullish technical signals from moving averages. The company shows robust fundamentals with a P/E of 6.06, net income margin of 24.52%, and ROE of 30.77%. Recent Q2 2026 earnings beat expectations at $1.62 EPS versus $1.52 expected. Positive developments include new oil discoveries and platform deployments boosting production capacity.
PBR presents compelling value with attractive valuation metrics and strong profitability, though current price sits near analyst consensus target of $22.33. Key risks include political interference in Brazil and capital expenditure pressures. The stock offers dividend yield potential with recent $0.53 dividend declaration, supported by 50% analyst buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
